Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523425 | 1.00 | — | — | |
| SCHEMBL17837 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL27486357 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD | |
| Bromide SCHEMBL27394282 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD | |
| SCHEMBL27753650 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD | |
| Hydrochloric Acid SCHEMBL27893779 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD | |
| SCHEMBL27692181 | 0.98 | — | — | |
| Methane SCHEMBL14738986 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD | |
| Potassium SCHEMBL30760557 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD | |
| SCHEMBL7639700 | 0.98 | AXL (0.95) | AXLNUDT1MAPK1CDK8PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9655888-B2 | Tricyclic alkene derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| EP-2696937-B1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-9586957-B2 | 2-keto amide derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-03-07 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9505752-B2 | Piperidine amide derivatives as HIV attachment inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
| CN-1612763-A | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | CN | disclosed |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| US-20050059695-A1 | Processes for the preparation of antiviral 7-azaindole derivatives | SOUNDARARAJAN NACHIMUTHU (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1487450-A1 | PROCESS FOR THE PREPARATION OF ANTIVIRAL 7-AZAINDOLE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1474135-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004011425-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO AND THIOUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003082289-A1 | PROCESS FOR THE PREPARATION OF ANTIVIRAL 7-AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003068221-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | AXL 4709/4885NUDT1 423/4885MAPK1 2806/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | AXL 4709/4885NUDT1 423/4885MAPK1 2806/4885 |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | IDO2, IDO1, INMT | AXL 4412/4885NUDT1 38/4885MAPK1 4093/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | AXL 4753/4885NUDT1 414/4885MAPK1 4407/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | AXL 4718/4885NUDT1 542/4885MAPK1 2626/4885 |
| US-20050059695-A1 | Processes for the preparation of antiviral 7-azaindole derivatives | MAVS, EIF2AK2, IMPDH1 | AXL 3809/4885NUDT1 29/4885MAPK1 2938/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | AXL 4709/4885NUDT1 423/4885MAPK1 2806/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | AXL 4709/4885NUDT1 423/4885MAPK1 2806/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | AXL 4709/4885NUDT1 423/4885MAPK1 2806/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | AXL 3210/4885NUDT1 744/4885MAPK1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.